The Serotonin Myth: Rethinking Depression and Antidepressants
Psychiatrist and researcher Joanna Moncrieff joins Mark Hyman to dismantle the 'chemical imbalance' theory of depression. Her 2022 review found no consistent evidence that low serotonin causes depression, and she argues antidepressants barely outperform placebo. The conversation reframes mental health around life circumstances, lifestyle, and individual root causes.
Overview
For decades, patients were told that depression stems from a serotonin deficiency that medication could correct. In this conversation, psychiatrist and researcher Joanna Moncrieff explains why that 'chemical imbalance' story never held up scientifically, citing her 2022 review that found no consistent evidence linking low serotonin to depression. She traces the idea to 1960s neurotransmitter theories that were fading until the pharmaceutical industry revived them in the late 1980s to market SSRIs like Prozac.
Moncrieff and Hyman examine how clinical trials show antidepressants barely outperform placebo, and how side effects can unblind studies to produce an 'amplified placebo' effect. They discuss real harms — emotional numbing, sexual dysfunction, and difficult withdrawal — and stress that these are active drugs that alter brain states rather than fix a disease. The pair reframe depression as a meaningful response to life circumstances, poor nourishment, chronic stress, and social and commercial pressures rather than a brain defect.
They explore diet through the SMILES trial, nutrient deficiencies, exercise, sleep, and the debated promise and risks of psychedelics. The through-line is Moncrieff's 'drug-centered' model and a hopeful takeaway: people retain the capacity to recover and change. As always, this is educational and not medical advice — any medication changes belong with your healthcare provider.
Key quotes
5What I object to most about telling people that they've got a chemical imbalance is that that is a really depressing message.
Depression is not a Prozac deficiency.
They are active drugs. They do have side effects. Most antidepressants seem to produce this sort of emotional numbing state.
There are as many causes of depression as there are people with depression.
We have been essentially lied to about the nature of depression for two and a half decades now.
Key ideas
8The Serotonin Myth
The idea that depression is caused by low serotonin became a public 'fact,' yet it was always a contested theory. Moncrieff set out to review the evidence objectively.
A Landmark 2022 Review
Her umbrella review of the serotonin research found no consistent evidence that depression is caused by low serotonin. Until then, the evidence had never been summarized clearly in one place.
Where the Idea Came From
First proposed in the 1960s around noradrenaline and serotonin, the theory was fading by the 1980s. The pharmaceutical industry then revived it to launch SSRIs.
Marketing a Brain Fix
To distance SSRIs from dependence-prone benzodiazepines, companies told patients they had an imbalance the drug would correct — a message repeated until it caught on.
Barely Better Than Placebo
Trials show antidepressants are minimally different from placebo, and design flaws — including non-blinding via side effects — likely inflate even that small gap.
Active Drugs, Not Corrections
Antidepressants are not placebos; they alter brain states and commonly cause emotional numbing, which is not the same as fixing an underlying disease.
Depression as a Life Response
1991 market research showed people once linked depression to unemployment, divorce, and abuse — an understanding buried by campaigns to medicalize distress.
Drug-Centered vs Disease-Centered
Like alcohol or psychedelics, psychiatric drugs superimpose an altered state onto underlying feelings rather than target a specific disease mechanism.
Practical takeaways
6- 1
Decide with a clinician 3:00
Use conversations like this as a starting point, not a reason to change medication alone. Treatment decisions belong with your healthcare provider.
- 2
Ask what the feeling signals 34:00
Try to identify what in your life is driving the emotion and what you might be able to change — a first step beyond the diagnostic label.
- 3
Never stop abruptly 27:00
Antidepressants require slow, careful tapering; stopping too quickly can cause severe withdrawal, especially after years of use.
- 4
Use deprescribing resources 57:00
The Maudsley Deprescribing Guidelines offer detailed, evidence-based guidance on reducing doses gradually with professional support.
- 5
Build lifestyle foundations 58:00
Whole-food eating, regular cardiovascular exercise, sleep and circadian rhythm, and stress regulation all measurably support mood.
- 6
Check common deficiencies 39:00
Nutrients such as omega-3s, vitamin D, folate, and B12 are linked to mood; correcting deficiencies is an accessible, evidence-informed step.
Topics & chapters
14A Hopeful Message
Moncrieff opens on why the chemical-imbalance story is demoralizing, followed by a note that this explores a debated area and is not medical advice.
Meet Joanna Moncrieff
Introducing her provocative book 'Chemically Imbalanced' and a shared intellectual history of challenging psychiatric orthodoxy.
The 2022 Serotonin Review
Why she conducted the landmark review and what it revealed about the missing evidence for a serotonin deficiency.
Origins in the 1960s
How noradrenaline and serotonin theories arose, were tested by the NIMH in the 1970s, and began to decline.
How Pharma Marketed SSRIs
The late-1980s revival of the imbalance idea to differentiate SSRIs from benzodiazepines and build a market.
Rigged Trials, Amplified Placebo
How trial design, non-blinding, and side effects inflate the tiny gap between antidepressants and placebo.
Emotional Numbing
Why these are active drugs with real effects — notably emotional numbness — rather than disease correctors.
Side Effects and Withdrawal
Sexual dysfunction, dependence, and the need to taper slowly while honestly acknowledging risk.
Reframing Depression
1991 market research and the older view of depression as an emotional reaction to life circumstances.
Biology, Diet, and SMILES
The SMILES trial, nutrient deficiencies, and Moncrieff's caution about any single biological mechanism.
Social and Commercial Determinants
Poverty, loneliness, trauma, learned helplessness, and industries that profit while undermining health.
The Psychedelic Question
Psilocybin, MDMA, ibogaine, and ketamine — their promise, the annuity problem, and unknown long-term risks.
Drug- vs Disease-Centered
Understanding psychiatric drugs as mind-altering substances superimposed on feelings, not disease-targeting agents.
Deprescribing and What Helps
Safe tapering, the Maudsley guidelines, distinguishing withdrawal from relapse, and lifestyle-based recovery.